The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
<p>Pneumococcal conjugate vaccines (PCVs) protect against invasive pneumococcal disease (IPD) among vaccinees. However, at population level, this protection is driven by indirect effects. PCVs prevent nasopharyngeal acquisition of vaccine-serotype (VT) pneumococci, reducing onward transmission...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado: |
Springer Nature
2023
|
| _version_ | 1826310707493208064 |
|---|---|
| author | Adamu, AL Ojal, J Abubakar, IA Odeyemi, KA Bello, MM Okoromah, CAN Karia, B Karani, A Akech, D Inem, V Scott, JAG Adetifa, IMO |
| author_facet | Adamu, AL Ojal, J Abubakar, IA Odeyemi, KA Bello, MM Okoromah, CAN Karia, B Karani, A Akech, D Inem, V Scott, JAG Adetifa, IMO |
| author_sort | Adamu, AL |
| collection | OXFORD |
| description | <p>Pneumococcal conjugate vaccines (PCVs) protect against invasive pneumococcal disease (IPD) among vaccinees. However, at population level, this protection is driven by indirect effects. PCVs prevent nasopharyngeal acquisition of vaccine-serotype (VT) pneumococci, reducing onward transmission. Each disease episode is preceded by infection from a carrier, so vaccine impacts on carriage provide a minimum estimate of disease reduction in settings lacking expensive IPD surveillance. We documented carriage prevalence and vaccine coverage in two settings in Nigeria annually (2016–2020) following PCV10 introduction in 2016. Among 4,684 rural participants, VT carriage prevalence fell from 21 to 12% as childhood (<5 years) vaccine coverage rose from 7 to 84%. Among 2,135 urban participants, VT carriage prevalence fell from 16 to 9% as uptake rose from 15 to 94%. Within these ranges, carriage prevalence declined with uptake. Increasing PCV10 coverage reduced pneumococcal infection at all ages, implying at least a comparable reduction in IPD.</p> |
| first_indexed | 2024-03-07T07:57:27Z |
| format | Journal article |
| id | oxford-uuid:62f16e6b-d5db-41d4-942b-0d488874721f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:57:27Z |
| publishDate | 2023 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:62f16e6b-d5db-41d4-942b-0d488874721f2023-08-30T09:17:42ZThe impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in NigeriaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:62f16e6b-d5db-41d4-942b-0d488874721fEnglishSymplectic ElementsSpringer Nature2023Adamu, ALOjal, JAbubakar, IAOdeyemi, KABello, MMOkoromah, CANKaria, BKarani, AAkech, DInem, VScott, JAGAdetifa, IMO<p>Pneumococcal conjugate vaccines (PCVs) protect against invasive pneumococcal disease (IPD) among vaccinees. However, at population level, this protection is driven by indirect effects. PCVs prevent nasopharyngeal acquisition of vaccine-serotype (VT) pneumococci, reducing onward transmission. Each disease episode is preceded by infection from a carrier, so vaccine impacts on carriage provide a minimum estimate of disease reduction in settings lacking expensive IPD surveillance. We documented carriage prevalence and vaccine coverage in two settings in Nigeria annually (2016–2020) following PCV10 introduction in 2016. Among 4,684 rural participants, VT carriage prevalence fell from 21 to 12% as childhood (<5 years) vaccine coverage rose from 7 to 84%. Among 2,135 urban participants, VT carriage prevalence fell from 16 to 9% as uptake rose from 15 to 94%. Within these ranges, carriage prevalence declined with uptake. Increasing PCV10 coverage reduced pneumococcal infection at all ages, implying at least a comparable reduction in IPD.</p> |
| spellingShingle | Adamu, AL Ojal, J Abubakar, IA Odeyemi, KA Bello, MM Okoromah, CAN Karia, B Karani, A Akech, D Inem, V Scott, JAG Adetifa, IMO The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria |
| title | The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria |
| title_full | The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria |
| title_fullStr | The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria |
| title_full_unstemmed | The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria |
| title_short | The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria |
| title_sort | impact of introduction of the 10 valent pneumococcal conjugate vaccine on pneumococcal carriage in nigeria |
| work_keys_str_mv | AT adamual theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT ojalj theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT abubakaria theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT odeyemika theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT bellomm theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT okoromahcan theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT kariab theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT karania theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT akechd theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT inemv theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT scottjag theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT adetifaimo theimpactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT adamual impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT ojalj impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT abubakaria impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT odeyemika impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT bellomm impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT okoromahcan impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT kariab impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT karania impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT akechd impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT inemv impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT scottjag impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria AT adetifaimo impactofintroductionofthe10valentpneumococcalconjugatevaccineonpneumococcalcarriageinnigeria |